ibandronic acid has been researched along with capecitabine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Bauerfeind, I; Conrad, B; du Bois, A; Elling, D; Fehm, T; Harbeck, N; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Schneeweiss, A; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Belau, A; Graf, H; Hofmann, M; Huober, J; Jackisch, C; Just, M; Krocker, J; Loibl, S; Nekljudova, V; Nitz, U; Reimer, T; Runnebaum, I; Schmatloch, S; Schmidt, M; Stickeler, E; Untch, M | 1 |
1 review(s) available for ibandronic acid and capecitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for ibandronic acid and capecitabine
| Article | Year |
|---|---|
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Dose-Response Relationship, Drug; Early Diagnosis; Epirubicin; Female; Filgrastim; Germany; Humans; Ibandronic Acid; Middle Aged; Paclitaxel; Polyethylene Glycols; Young Adult | 2017 |
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Ibandronic Acid; Middle Aged | 2023 |